{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-141087","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.212200+00:00","generated_at":"2026-05-19T06:34:10.388431+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Intellia reports 98% reduction in HAE attacks with lonvo-z over 3 years in Phase 1","bullets":["Single dose led to mean 98% reduction in monthly HAE attack rate across all 10 patients.","All patients attack-free and treatment-free for median 23 months at data cutoff.","No treatment-emergent serious adverse events; infusional reactions mostly Grade 1, all resolved.","Phase 3 HAELO trial screening completed ahead of schedule; >50% screened in U.S.","Expects BLA submission in 2026 and U.S. launch in 2027, pending FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-141087","json":"https://secwatch.observer/filing/0001193125-25-141087.json","markdown":"https://secwatch.observer/filing/0001193125-25-141087.md","text":"https://secwatch.observer/filing/0001193125-25-141087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525141087/0001193125-25-141087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525141087/d82485d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:34:10.388431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}